Full Press Release Details
Sanofi s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director
PARIS, France March 6,
2018 - At its meeting held on March 6, 2018, Sanofi s Board of Directors proposed to submit the appointment of Emmanuel Babeau as new independent director, as well as the renewal of the terms of Olivier Brandicourt, Patrick Kron and
Christian Mulliez to a shareholders vote during the general shareholders meeting on May 2, 2018. Robert Castaigne, board member since 2000 and current Chair of the Audit Committee, will not seek a new term. Fabienne Lecorvaisier will
succeed him as Chair of the Audit Committee. The Board has also created a new Scientific Committee, which will be led by Thomas S dhof.
Babeau is Deputy Chief Executive Officer and Chief Financial Officer of Schneider Electric Group, a position he has held since April 2013. He joined Schneider Electric in 2009 as Chief Financial Officer. Before joining Schneider Electric Group, he
was Group Chief Financial Officer of Pernod Ricard SA from 2003 to 2009. Emmanuel Babeau graduated from Ecole sup rieure de commerce de Paris in 1989 with a degree in accounting and financial.
Throughout his career Emmanuel Babeau led successful acquisitions and developed strong financial skills with an international mindset
that will be strong additions to our Board. We are confident that his contribution to Sanofi s strategy will be beneficial in bringing innovative medicines to the market, said Serge Weinberg, Chairman of the Board,
Sanofi. I would like to thank Robert Castaigne for his strong contribution to the board and as Chairman of the Audit Committee since March 2015 and wish all the best to Fabienne Lecorvaisier who
will succeed him as Chair of the Audit Committee.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness
with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates regarding the clinical development of and potential marketing approvals for the product. Forward-looking statements are generally identified
by the words expects , anticipates , believes , intends , estimates , plans , would be and similar expressions. Although Sanofi s management believes that the
expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among
other things, the uncertainties inherent in research and development of the product, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve
the product or biological application that may be filed for the product as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of the product, the absence of guarantee that the
product if approved will be commercially successful, risks associated with intellectual property, future litigation, the future approval and commercial success of therapeutic alternatives, and volatile economic conditions, as well as those risks
discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofi s annual report on
Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.